Open Beta
TREN
MetriLume
TREN

US marketsAMRN

SEC-sourced researchBeta

AMRN

AMARIN CORP PLC\UK

Company comparison ↗

Data passport

CIK
0000897448
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Aug 27, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 306,911,000.0000 USD; December 2024: 228,614,000.0000 USD; December 2025: 213,646,000.0000 USD306.9M USD0 USD0December 2023December 2024December 2025
AMRN · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023306,911,000.0000Mar 2, 2026
December 2024228,614,000.0000Mar 2, 2026
December 2025213,646,000.0000Mar 2, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025213,646,000.0000-38,798,000.00006,728,000.0000670,775,000.0000211,494,000.0000Mar 2, 2026
December 2024228,614,000.0000-82,183,000.0000-31,020,000.0000685,349,000.0000199,173,000.0000Mar 2, 2026
December 2023306,911,000.0000-59,112,000.00006,880,000.0000——Mar 2, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

56/100
Profitability14
Growth43
Balance sheet68
Cash generation56
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$213.65MJan 1, 2025 – Dec 31, 2025Mar 2, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$228.61MJan 1, 2024 – Dec 31, 2024Mar 2, 202610-K
Net incomeNetIncomeLoss-$38.8MJan 1, 2025 – Dec 31, 2025Mar 2, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$6.73MJan 1, 2025 – Dec 31, 2025Mar 2, 202610-K
Total assetsAssets$670.78MDec 31, 2025Mar 2, 202610-K
Total liabilitiesLiabilities$211.49MDec 31, 2025Mar 2, 202610-K

New filings

Explore methodology ↗